Corporate Member News
Subscribe to receive Corporate Member News notifications!
Thank You! Please check your email inbox to confirm your subscription.
7/28/2025
LYNOZYFIC is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.
Loading ...
Powered By GrowthZone